Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
A number of AIM companies have experienced all time high share prices due to Covid and their test offerings. Now that Covid is perceived to be over, stock prices have been realigned. Covid and Covid testing is far from over.
LTH’s invested in Avacta pre-Covid and invested for the therapeutic side of the business. The expectation was for the diagnostics (LFT’s) to provide income that would support the successful launch of AVA6000, AVA3996 and other life changing therapeutic products.
Avacta has cash in the bank and the game changing therapeutics are in trials. LTH’s are expecting positive AVA6000 news in the coming weeks along with a share price correction.
Some companies listed on AIM will fail. Those who invested in Avacta for LFT’s over the past 12 months will be sitting on a paper loss. Demand for accurate LFT’s will remain and the therapeutics news in coming.
Please DYOR before making any rash decisions.
12 Month High and Current:
ABDX down from £ 1.36 to £ 0.20 (-85%)
AVCT down from £ 2.80 to £ 0.77 (-72%)
GDR down from £ 1.58 to £ 0.19 (-88%)
NCYT down from £ 12.06 to £ 2.66 (-78%)
ODX down from £ 1.04 to £ 0.13 (-87%)
Thank you to Mr Ripley for posting the link below earlier.
https://mobile.twitter.com/MylesMcNulty/status/1483101405980381190
Interesting and positive read for all, hence the repost.
Still a lot to offer, .....
Therapeutics
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy.
Avacta entered the clinic with its lead pre|CISION™ programme AVA6000, a tumour activated form of doxorubicin, in summer 2021.
Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTx, Inc., a development and commercialisation deal with LG Chem worth up to $310m and a collaboration with ADC Therapeutics to develop novel Affimer® drug conjugates. The Company is actively seeking to license its proprietary platforms in a range of therapeutic areas.
Diagnostics
Avacta aims to become the leading provider of innovative, next generation diagnostic solutions, and the first choice for disruptive immunodiagnostic products.
Our diagnostics division is utilising our proprietary Affimer® platform to develop AffiDX®in vitro diagnostic (IVD) tests, starting with the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test.
We have also established commercial relationships with IVD companies worldwide to improve the clinical utility of diagnostic testing solutions, by combining bespoke Affimer® reagents with leading diagnostic platform technologies.
RNS Monday 10th January 2022:
We were all waiting for an LFT RNS and this was not it. Share price has tumbled as a result. Many, including me, feeling the pain.
The Affimer reagent is not the problem. Selecting a more suitable antibody to work with Omicron and future variants is the current challenge. A matter of weeks?
Moving On:
So, let’s put on our rational heads and think about where we are.
- LFT’s are on hold but may generate future revenues.
- Share price down 70% from £ 2.90 high to around £ 0.85, (ouch!)
- Avacta is non-profitable but is funded into 2023.
- Avacta has unique and innovative IP.
- The Affimer science has been shared other global partners.
- The Affimer science (AVA6000) is in cancer treatments trials.
- Other Affimer based products are in development / trials.
Avacta is at a critical stage in the business journey.
There will be further updates but not expecting any major RNS news for a few weeks now.
RNS Monday 10th January 2022:
We were all waiting for an LFT RNS and this was not it. Share price has tumbled as a result. Many, including me, feeling the pain.
The Affimer reagent is not the problem. Selecting a more suitable antibody to work with Omicron and future variants is the current challenge. A matter of weeks?
Moving On:
So, let’s put on our rational heads and think about where we are.
-LFT’s are on hold but may generate future revenues.
Share price down 70% from £ 2.90 high to around £ 0.85, (ouch!)
Avacta is non-profitable but is funded into 2023.
Avacta has unique and innovative IP.
The Affimer science has been shared other global partners.
The Affimer science (AVA6000) is in cancer treatments trials.
Other Affimer based products are in development / trials.
Avacta is at a critical stage in the business journey.
There will be further updates but not expecting any major RNS news for a few weeks now.
Number of LSE chats posted today:
Avacta = 96
Aviva = 5
Easyjet = 0
HSBC = 2
M&S = 7
Tui = 0
For a company that has failed and is doomed, there are a lot of people still discussing Avacta. Ignore the negativity, Avacta is just getting started.
Wait for the BIG news.
A number of approved suppliers will drop of the list at the end of February. If they can no longer supply to the UK market, this will create LFT shortages. This fits in with the latest HMG thinking to stop issuing free LFT’s.
Opportunity (UK) for Avacta subject to CTDA home use approval and increased manufacturing volumes?
Alternatively, there is global demand for accurate LFT’s. Complete TT’s, ramp up the volumes and ship LFT’s to Europe, Asia and the USA.
Something coming?
https://www.medusa19.com/en/
For anyone who has not read the Daily Mail article.
Link:
https://www.dailymail.co.uk/news/article-10365883/The-lateral-flow-tycoons-tiny-UK-firm-20m-profit-thanks-Covid-role.html
Tim Peto, said that companies were “whingeing” when their tests did not perform well enough. “Some of the English manufacturers are very unhappy their kits have failed and some of them think that they’ve been unfairly tested. I don’t know on what grounds they think it’s unfair other than it came out negative.”
Perhaps Tim Peto needs to discuss with the manufacturers and understand why they think it’s unfair?
@Gruffell
Thank you for posting the Sunday Times article.
Avacta CTDA application submitted before September 2021 but claims that there are no backlogs. Something not right here. Hopefully all the UK press will now get on this story and the facts will come out.
It will be interesting to read and hear what next week brings.
There have been a few comments relating to updates on websites.
Websites can be updated off-line with the updates not posted or made live. I suspect updates have been made but they are waiting a coordinated publication after 4th January 2022.
The Avacta LFT (approvals, production and sales) is big news and we would not want this major news to go unnoticed during the holiday period. Still think there will big be news next week.
Happy & Healthy New Year everyone. Stay Safe.